sintilimab,IBI939
innovent biologics,eli lilly
['nsclc', 'sintilimab', 'sclc', 'innovent']
innovent updates phase 1b data of ibi939 (anti-tigit monoclonal antibody) combined with sintilimab in previously untreated pd-l1-selected nsclc at the 2023 asco annual meeting #prnewswire #prnewswire 
Stock Market News and Press Releases. #StockMarket & #Crypto